Purpose Boron neutron capture therapy (BNCT) has the potential to become a viable cancer treatment modality, but its clinical translation has been limited by the poor tumor selectivity of agents. To address this unmet need, a boronated 2-nitroimidazole derivative (B-381) was synthesized and evaluated for its capability of targeting hypoxic glioma cells. Methods B-381 has been synthesized from a 1-step reaction. Using D54 and U87 glioma cell lines, the in vitro cytotoxicity and cellular accumulation of B-381 has been evaluated under normoxic and hypoxic conditions compared to Lboronophenylalanine (BPA). Furthermore, tumor retention of B-381 was evaluated in vivo. Results B-381 had low cytotoxicity in normal and cancer cells. Unlike BPA, B-381 illustrated preferential retention in hypoxic glioma cells compared to normoxic glioma cells and normal tissues in vitro. In vivo, B-381 illustrated significantly higher long-term tumor retention compared to BPA, with 9.5-fold and 6.5-fold higher boron levels at 24 and 48 h, respectively. Conclusions B-381 represents a new class of BNCT agents in which their selectivity to tumors is based on hypoxic tumor metabolism. Further studies are warranted to evaluate B-381 and similar compounds as preclinical candidates for future BNCT clinical trials for the treatment of glioma. 
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INTRODUCTION
Glioblastoma multiforme (GBM) is an aggressive astrocytoma and is the most common primary brain tumor in adults (1) . The current standard of care for treating GBM is surgical resection (when operable) followed by radiation therapy (XRT) with concomitant and adjuvant temozolomide treatment (2, 3) . Even with this aggressive therapeutic regimen, GBM patients still have a poor prognosis: 2-and 5-years survival rates of 10 and 1%, respectively (4) . Current treatment provides only a modest boost to patient survival, and a myriad of radiation-and chemotherapy-induced side effects plague the quality of life for these patients. Even with therapy, patients experience a high recurrence rate of approximately 90% (5) . Therefore, new approaches that reduce off-target side effects, improve efficacy and extend patient survival are direly needed. Boron neutron capture therapy (BNCT) is an emerging treatment modality with the potential to minimize side effects and improve GBM patient survival (6) . BNCT utilizes the neutron capture reaction of boron-10 ( 10 B) and its subsequent nuclear fission reaction to produce cellular death (7) . After a 10 B atom absorbs a neutron, the resulting unstable 11 B isotope undergoes a nuclear fission reaction releasing an alpha particle, lithium-7 ion and gamma radiation (8) . The path lengths of these newly generated linear energy transfer particles are typically 5-9 μm, thereby localizing the cytotoxic effect (8) . Additionally, the cytotoxic effect is further localized since the nuclear fission reaction will only occur in boron-containing cells that fall within the neutron irradiation field.
Unlike radiation therapy, BNCT uses a non-ionizing neutron beam for irradiation. Therefore, if boron selectively accumulates in the tumor and minimally in the surrounding tissue, the off-target radiation effects common to traditional radiation therapy will be mitigated in BNCT. To date, Lboronophenylalanine (BPA) and sodium borocaptate (BSH) are the most commonly investigated BNCT agents in clinical studies. The challenge in developing an efficacious BNCT agent is to achieve adequate tumor/normal tissue (T/N) and tumor/blood concentration ratios (ideally greater than 3:1). Not only must an agent have a preferential tumor accumulation, it must also have limited systemic cytotoxicity.
High grade glioma patients enrolled in BNCT clinical trials have affirmed that BNCT is tolerated well and has comparable (or fewer) side effects than conventional XRT (9, 10) . However, the median survival times of these trials was comparable to the standard of care (XRT and temozolomide). BPA and BSH typically have T/N ratios < 3 clinically which limits their therapeutic efficacy (7) . These results emphasize the need to develop novel compounds with higher tumor specificity and improved T/N ratios.
GBM consists of a heterogeneous tumor microenvironment containing areas of differing oxygenation levels which reflect unique metabolic patterns (11) . Highly oxygenated regions (close proximity to blood vessels) are characterized with fast tumor proliferation and oxidative metabolism (12) , while hypoxic regions (with low oxygenation) are characterized with low proliferation and reductive metabolism (13) . Hypoxic conditions in GBM tumors have been shown to decrease cell proliferation (14) , induce metastasis (15) , promote angiogenesis (16) , and confer resistance to chemotherapy (17) and XRT (18) . Resistance has been attributed to the development of a subpopulation of cancer stem-like cells (19) that contribute to relapse in GBM (20, 21) .
It has long been recognized that 2-nitroimidazole derivatives are capable of selectively accumulating in hypoxic cells (22, 23) . In the current study, we hypothesized that a boronated nitroimidazole derivative will preferentially accumulate in the tumor while sparing the surrounding (normoxic) healthy tissue, thereby improving the boron T/N ratio. In this study, we present the chemical synthesis and biological evaluation of the boronated nitroimidazole derivative B-381. This derivative had low toxicity and a preferential accumulation in hypoxic glioma cells, making it a suitable candidate for future BNCT studies.
MATERIALS AND METHODS

Reagents and Cell Culture
All synthetic reagents for the chemical synthesis were purchased from Sigma Aldrich (St. Louis, MO). Glioma (D54 and U87) and hippocampus (HT22) cell lines were a kind gift from Dr. Dinesh Thotala (Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine). All cell lines were cultured in Dulbecco's Modified Eagle's Medium (DMEM, Corning CellGro, Mediatech, Manassas, VA) supplemented with 20% fetal bovine serum (FBS, Gibco, Life Technologies, Grand Island, NY), 2 mmol/L of L-glutamine, 100 U/mL Penicillin and 100 μg/mL Streptomycin (CellGro, Mediatech, Manassas, VA). Before plating, cells were washed with phosphate-buffered saline (PBS, Corning CellGro, Mediatech, Manassas, VA), trypsinized with 0.05% Trypsin-EDTA 1× (Gibco, Life Technologies, Grand Island, NY), spun for 5 min (1000 RPM) and resuspended in fresh DMEM media. Peripheral blood mononuclear cells (PBMCs) were isolated from pheresis leukopaks from the Siteman Cancer Center (Washington University in Saint Louis). Red Blood Cell Lysis Buffer 1× (BioLegend, San Diego, CA) was added to whole blood, gently vortexed and incubated at room temperature for 15 min (protected from light). PBMCs were washed with PBS and resuspended in fresh DMEM media. For normoxic conditions, cells were cultured at 37°C (5% CO 2 ) in a NuAire water jacket incubator (Plymouth, MN). For hypoxic conditions, cells were cultured at 37°C with 0.5% O 2 concentration in a hypoxic chamber (Coy Laboratory Products, Grass Lake, MI).
Synthesis of Boronated 2-Nitroimidazole Derivative B-381
Piperidine-4-boronic acid pinacol ester hydrochloride (73 mg, 0.296 mmol) was dissolved in saturated sodium bicarbonate solution (1 mL). Ethanol (50 mL) was added, mixed for several minutes, and was followed by addition of sodium sulfate (until no clumping was observed). This mixture was filtered and transferred to a 100 mL round bottom flask. Thereafter 1-(2,3-Epoxypropyl)-2-nitroimidazole (50 mg, 0.296 mmol) was added and the mixture refluxed for 5 h. After the starting material was consumed, the mixture was concentrated on a rotary evaporator. Methanol was added to the crude oil resulting in precipitation of the product B-381 (IUPAC name: 1-(2-nitro-1H-imidazol-1-yl)-3-(4-(4, 4,5, 5-tetramethyl-1 ,3,2 -dio xabor olan-2-yl)piperidin-1-yl)propan-2-ol). The precipitate was isolated and the chemical structure was confirmed by liquid chromatography-mass spectrometry and proton nuclear magnetic resonance ( 1 H-NMR) spectroscopy. The molecular weight of the product was confirmed to be 381 g/mol, giving rise to the compound abbreviation B-381.
Cell Viability Assay
Cell viability was assessed by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay as described previously (24) . Briefly, HT22, PBMCs, D54 and U87 cell lines were cultured in normoxia (21% O 2 ) or hypoxia (0.5% O 2 ) and treated for 24 h or 72 h with B-381 or BPA (0, 0.01, 0.1, 1, 10, 100 μM). After treatment, MTT solution was added for 3 h followed by the addition of 10% sodium dodecyl sulfate solution. The absorbance was read the following day at 570 nm using a plate reader.
HPLC Assay for B-381 Detection
B-381 was analyzed using high performance liquid chromatography (HPLC, Agilent 1100 series, Santa Clara, CA) with a reverse phase C-18 column (Agilent Zorbax Eclipse XDB C18), at a flow rate of 1 mL/min and operating pressure range of 70-85 Barr. An acetonitrile gradient containing 0.1% trifluoroacetic acid was used as the mobile phase: the gradient was increased from 0 to 10% acetonitrile (from time 0 to 7 min) and then decreased back to 0% acetonitrile (from time 7 to 14 min). A calibration curve was formed by plotting the area under curve (AUC) of the B-381 HPLC peak (at retention time = 5 min, λ = 330 nm) for the concentration range of B-381 (0 to 10 μg/mL). The linear correlation for the curve had a R 2 = 1, with a limit of detection approximately 0.1 μg/mL.
Cellular Uptake of B-381 In Vitro
PBMCs, D54, U87 or HT22 cells (1 × 10 6 cells/well) were cultured overnight under normoxia. The following day, cells were incubated in normoxic or hypoxic conditions for 4 h in serum free media, then B-381 was added with a final concentration of 10 μg/mL for 48 h. Additionally, B-381 solution was added to wells with no cells to serve as a no-cellular uptake control. It was observed that the AUC remained constant for this control over the experimental timeline. Media samples were collected from each well at 0 and 48 h, and analyzed by the aforementioned HPLC assay for B-381 concentration. P e r c e n t u p t a k e o f B -3 8 1 w a s c a l c u l a t e d a s % Uptake = [(AUC Control -AUC Sample )/AUC Control ]*100.
Cellular Uptake of BPA In Vitro
PBMCs, D54, U87 or HT22 cells (1 × 10 6 cells/well) were cultured overnight under normoxia. The following day, cells were incubated in normoxic or hypoxic conditions for 4 h in serum free media, then BPA was added with a final concentration of 10 μg/mL for 48 h. Also, BPA solution was added to wells with no cells to serve as a no-cellular uptake control. Media samples were collected from each well at 0 and 48 h, and then were digested with concentrated nitric acid for 2 days. Samples were diluted with deionized water to a final acid concentration of 5% (v/v) and were filtered through a 0.22 μm polyethersulfone syringe filter (DiKMA Technologies, Lake Forest, CA) and analyzed using Inductively Coupled Plasma Optical Emission Spectrometry (ICP-OES, Optima 7300 V series, Perkin Elmer, Waltham, MA). Samples were analyzed for boron content (λ = 249.677 nm) against a calibration curve of boron standards of 0, 5.2, 15.625, 31.25, 62.5, 125 and 250 parts per billion (ppb) prepared from a 10 parts per million boron standard solution (Inorganic Ventures, Christiansburg, VA). BPA p e r c e n t u p t a k e w a s c a l c u l a t e d a s % Uptake = [(Boron Control -Boron Sample )/Boron Control ]*100.
Tumor Retention Study of BPA and B-381 In Vivo
Approval for all animal studies was obtained from the Ethical Committee for Animal Experiments at Washington University in St. Louis Medical School. Athymic NudeFoxn1 nu mice (N = 10, females, 6 week old) were obtained from Envigo (Indianapolis, IN). Mice were anesthetized with ketamine/xylazine and bilaterally injected with 3.5 × 10 6 D54 glioma cells under the skin of each hindlimb (two injections per mouse). Two weeks post-injection both tumors were palpable under the skin. The mice were split into control (N = 1) or treatment (N = 9) groups. Each mouse in the treatment group was anesthetized and received two intratumoral injections: the left tumor received BPA (23.3 mg/kg mouse, equivalent to 0.02 mmol boron/mouse) while the right tumor received B-381 (42.9 mg/kg mouse, equivalent to 0.02 mmol boron/mouse). Mice were sacrificed at 8 (N = 3), 24 (N = 3) and 48 (N = 3) h post-injection, and tumors were excised, weighed and digested in concentrated nitric acid. Samples were diluted with deionized water to a final acid concentration of 5% (v/v) and analyzed by ICP-OES for boron content which was normalized to tumor weight (reported as ng of boron/g of tumor (ppb)).
B-381 In Vivo Biodistribution Study
Five (N = 5) athymic Nude-Foxn1 nu mice were subcutaneously injected with 3.5 × 10 6 D54 glioma cells in their back. When the subcutaneous tumors were large and visible, four mice each received a 200 μL intravenous (i.v.) tail vein injection of B-381 (dose 100 mg/kg in 10% w/v captisol solution). The fifth mouse did not receive an injection and was used as control. After 24 h, the mice were anesthetized, blood samples were collected, and the tumors were resected. Blood and tumor samples were weighed and digested in nitric acid. After diluting to a final acid concentration of 5% (v/v) with deionized water, samples were analyzed for boron concentration by ICP-OES and normalized to blood or tumor mass.
Plasma Half-Life Study of B-381 In Vivo
Six C57BL/6 mice (N = 6) were intravenously injected with B-381 (50 mg/kg in 10% w/v captisol). Blood was collected from the mice under anesthesia using a submandibular bleeding technique (25) at 5 min, 1, 2, 4, 6 and 24 h (n ≥ 3 for each time point). The blood samples were weighed, digested in nitric acid and analyzed by ICP-OES for boron concentration (normalized to mass of each blood sample).
RESULTS
Synthesis and Characterization of Boronated Nitroimidazole Derivative B-381
In an effort to design a BNCT agent capable of targeting the hypoxic tumor microenvironment, a facile 1-step synthesis of a boronated 2-nitroimidazole derivative was envisioned. In short, commercially available piperidine-4-boronic acid pinacol ester and 1-(2,3-epoxypropyl)-2-nitroimidazole were refluxed in anhydrous ethanol to afford the boronated 2-nitroimidazole derivative termed B-381 (Figure 1a ). The resulting product had a corresponding mass to charge (m/z) ratio of 381.6 (Figure 1b) , and the structure was further validated by 1 H NMR spectroscopy (Figure 1c) .
The Effect of B-381 and BPA on Viability of Normoxic and Hypoxic Cells In Vitro
We next evaluated the effect of B-381 compared to the extensively studied BNCT agent BPA on cell viability. In normoxia (21% O 2 ) B-381 illustrated minimal cytotoxicity in all cell lines evaluated (D54, U87, HT22 and PBMCs) up to concentrations of 100 μM (Figure 2a) . The cytotoxicity profile of B-381 was nearly identical under hypoxia (0.5% O 2 ) (Figure 2b ). In comparison, BPA showed minimal cytotoxicity at concentrations up to 100 μM in all cell lines evaluated in both normoxic (Figure 2c ) and hypoxic (Figure 2d) conditions. Additionally, the long-term cytotoxicity of B-381 was evaluated in normoxia and hypoxia for the D54 cell line. Even after a 72 h treatment of B-381 up to concentrations of 100 μM, no cytotoxicity was observed (Supplementary Figure 1) .
Cellular Uptake of B-381 and BPA in Normoxic and Hypoxic Cells In Vitro
For evaluating the in vitro cellular uptake of B-381, a reverse phase HPLC assay was developed. B-381 had a retention time of 5 min (Figure 3a) and illustrated a linear dynamic range in the concentration range between 0 and 10 μg/mL with a R 2 = 1 (Figure 3b ). Cells were treated for 48 h with 10 μg/ mL of B-381 under normoxia (PBMCs, HT22, D54 and U87) or hypoxia (D54 and U87). Percent uptake was calculated by comparing the AUC values for B-381 in media aliquots at 0 and 48 h time points. In all cell lines treated under normoxic conditions (PBMCs, HT22, D54 and U87), B-381 had a low percent cellular uptake of < 5% after 48 h. In contrast, D54 and U87 glioma cell lines treated under hypoxia had significantly higher B-381 uptake of 21 and 25%, respectively (Figure 3c ). Subsequently the in vitro cellular uptake of BPA was evaluated using ICP-OES. Boron standards between 0 and 250 ppb had a linear dynamic range with a R 2 = 0.9992 (Figure 3d ). Using 10 μg/mL of BPA under normoxia (PBMCs, HT22, D54 and U87) or hypoxia (D54 and U87), BPA had a low percent uptake of approximately < 5% in all conditions evaluated (Figure 3e ). These results indicate that B-381 preferentially accumulates in hypoxic glioma cells compared to BPA.
Tumor Retention, Biodistribution and Pharmacokinetics of B-381 In Vivo
To eliminate the biodistribution and metabolic components associated with B-381 administration, an intratumoral injection of B-381 was compared to BPA in order to verify the tumor retention of B-381 due to its presumed formation of protein conjugates in a hypoxic microenvironment. To compare the in vivo tumor accumulation of B-381 and BPA, a D54 glioma xenograft mouse model was utilized. Mice containing bilateral hindlimb D54 glioma tumors were intratumorally injected with equimolar concentrations of BPA or B-381. Following injection, mice were sacrificed at 8, 24 or 48 h. Tumors were excised, digested and boron concentration was determined with ICP-OES. The tumor concentration of BPA and B-381 was nearly identical 8 h post-injection (1,595 ± 274 ppb and 1,130 ± 152 ppb, respectively, Figure 4a) . However, at 24 and 48 h post-injection, the concentration of BPA was almost undetectable. In contrast to BPA, the tumor demonstrated a long-term retention of B-381, with 9.5-fold and 6.4-fold higher boron levels at 24 and 48 h, respectively. Following the observed preferential hypoxic tumor accumulation of B-381 in vivo (Figure 4a ), the biodistribution of B-381 was investigated. Five (N = 5) athymic nude mice containing subcutaneous D54 glioma tumors were treated with B-381. Four mice received an i.v. injection of B-381, while the fifth mouse did not receive an injection and was used as a control. After 24 h, the boron content in tumor and blood was determined by ICP-OES. B-381 had preferential tumor accumulation, in which average tumor boron levels were 89.9 ± 18.9 ppb, while blood levels were 34.2 ± 8.0 ppb (Figure 4b ). This correlated to a tumor/blood ratio of 2.6.
An in vivo pharmacokinetic study was performed to determine the plasma half-life (T 1/2 ) for B-381. In brief, C57BL/6 mice received an i.v. injection of B-381. Blood was collected at 5 min, 1 h, 2 h, 4 h, 6 h and 24 h post-injection, and boron levels were determined by ICP-OES (Figure 4c) . Immediately following i.v. injection, a maximal boron level of 3,205 ± 458 ppb was detected (time = 5 min). Based on first order elimination kinetics, it was determined that B-381 was quickly eliminated from the blood with a T 1/2 = 2.09 h.
DISCUSSION
BNCT is a promising therapeutic approach based on the nuclear fission reaction of boron that is triggered by neutron irradiation. The resulting intracellular production of highenergy alpha particles can target tumor cells for destruction while having less off-target associated cytotoxicity compared to XRT and chemotherapy (6, 7) . However, the potential of BNCT to have a targeted tumoricidal effect is limited by the ability of a boronated agent to accumulate specifically in the tumor (ideally T/N > 3). Clinical trial agents BPA and BSH in glioma have suffered from poor tumor selectivity, with T/N ratios of 1.1-2.9 for BPA (10, 26, 27) and 0.7-3.6 for BSH (28) (29) (30) . Therefore, in order for the full therapeutic potential of BNCT to be realized, there is an urgent need to develop novel boronated tumor selective compounds.
To improve tumor selectivity in the setting of glioma, we envisioned that the hypoxic tumor microenvironment could be exploited as a targeting strategy. Hypoxic tumor cells contribute to chemotherapy (17) and XRT (18) resistance. Various factors such as increased expression of drug efflux pumps, decreased cell proliferation and oxygen-dependent cytotoxicity all play important factors in hypoxia-mediated drug resistance (13) . It was previously shown that these hypoxic areas have more reductive rather than the normal-cell oxidative metabolism (13), and we hypothesized that this property could be used to specifically target these tumor regions.
It has long been recognized that 2-nitromidazole derivatives can selectively accumulate in hypoxic cells. The most recognized 2-nitroimidazole derivative is pimonidazole, which is a gold-standard immunohistochemical marker of hypoxia (31) . In hypoxia, the nitro functional group undergoes a series of reductions and is converted to an amine (32) . This thereby makes the nitroimidazole ring susceptible to forming intracellular protein conjugates with thiol-containing proteins such as glutathione, which in turn causes accumulation of the nitroimidazole derivative in hypoxic cells. In an oxygen rich (normoxic) environment, the nitro functional group remains in its oxidized form, thereby preventing the formation of the aforementioned protein conjugates. This differential metabolism in normoxic and hypoxic cells has been utilized to develop a PET imaging agent for hypoxic tumor regions. 18 FFluoromisonidazole is a clinically used fluorinated-2-nitroimidazole PET agent for monitoring tumor hypoxia in glioma patients (20) . Therefore, we hypothesized that synthesizing a boronated 2-nitromidazole derivative should be able to selectively deliver boron to hypoxic glioma cells.
Herein we report the synthesis of B-381, which is a new boronated derivative of 2-nitroimidazole (Figure 1a) . B-381 is readily synthesized from a one-step reaction with commercially available precursors and is easily purified as a precipitate in methanol. After precipitation, B-381 has a clear mass Figure 2 The effect of B-381 and BPA on viability of normoxic and hypoxic cells in vitro: The effect of a 24 h treatment with B-381 (a and b) and BPA (c and d) on the viability of PBMCs from healthy subjects, hippocampal cell line HT22, and glioma cell lines D54 and U87 when cultured in normoxia (a and c) and in hypoxia (b and d). Viability was analyzed using MTT assay normalized to untreated control. spectrum (Figure 1b) with a single major peak observed on the HPLC chromatogram (Figure 3a) . Consistent with the structure of B-381, we observed a characteristic singlet peak in the 1 H NMR spectrum (integrating to 12 protons) that is a result of 4 methyl groups found in the pinacol ester group. Additionally, the aromatic region contained 2 nitroimidazole ring protons, while the remaining NMR peaks in the aliphatic region accounted for the final 14 protons (Figure 1c) .
In order to be a suitable drug candidate for BNCT, the boronated agent must have low systemic cytotoxicity (7). Dose-limiting toxicities could prevent sufficient tumor boron levels being reached which are required for BNCT to achieve a therapeutic effect. The cytotoxicity profile of B-381 in both normoxia and hypoxia is analogous to routinely studied BPA, and concentrations up to 100 μM can be studied with minimal cytotoxicity (Figure 2) . Additionally, B-381 exhibited a superior cytotoxic profile compared to BSH, which has an IC 50 value of 2.5 μM (33).
While BPA and BSH are the most extensively studied BNCT agents, their suboptimal T/N ratios observed in patients (usually T/N < 3) limits the efficacy of BNCT (7) . An ideal BNCT agent would have minimal systemic cytotoxicity and most importantly selective tumor accumulation with a T/N ratio of 3:1 or greater (6, 8, (34) (35) (36) (37) (38) (39) . In vitro cellular uptake studies show that B-381 selectively accumulated in a hypoxic tumor environment. Specifically, B-381 accumulated 4.1-fold higher in hypoxic D54 and 8.6-fold higher in hypoxic U87 cells compared to their normoxic controls. Additionally, compared to HT22, cellular uptake of B-381 in hypoxic D54 and U87 translated into T/N ratios of 4.4 and 5.3, respectively. On the other hand, the clinically used compound BPA showed very low uptake of boron in the cells, and showed poor tumor selectivity. The level of B-381 tumor selectivity satisfies requirements for effective BNCT and should be adequate to minimize off-target side effects to normal brain cells. Furthermore, the tumor selectivity of B-381 is higher than clinical T/N ratios achieved with BPA and BSH, which commonly have a T/N ratio between 0.7 and 3.6 (10, (26) (27) (28) (29) (30) .
Intratumoral injection of B-381 in vivo showed that it was selectively retained in the tumor significantly longer than BPA. While tumor boron levels were almost undetectable in the tumor at 24 and 48 h post-injection of BPA, B-381 had significantly longer tumor retention with values at 24 h similar to boron levels at 8 h. These results may be a direct result of B-381 forming intracellular protein conjugates in the hypoxic tumor microenvironment, which would be consistent with the in vitro results and with the known mechanism of 2-nitroimidazole compound accumulation. The long-term retention of B-381 can offer a clinical advantage compared to BPA, providing a longer therapeutic window for neutron irradiation.
In addition to the selective tumor retention, the tumor/blood ratio is an important factor to demonstrate selective uptake in the tumor and prevent damage to normal blood vessels during BNCT. To determine the tumor/blood ratio of B-381, mice received an i.v. injection of B-381 and boron levels were detected in the tumor and blood 24 h post-injection. We found that B-381 accumulated in the tumor against the concentration gradient, in which the tumor boron level was about 3-fold higher than the blood. These findings again indicate that B-381 is a good candidate for use in BNCT. However, we observed relatively low levels of tumor boron accumulation following i.v. injection of B-381, which can be attributed to fast elimination of the drug from the plasma. Therefore, we performed a pharmacokinetic analysis of B-381 following i.v. injection which found that it was quickly eliminated from the plasma (T 1/2 = 2.09 h). Thus, it is not surprising that the tumor boron content was lower following the i.v. injection. This is a classic drug delivery problem, where a drug is effective in the tumor environment but suffers from poor pharmacokinetics. Therefore, to maximize its tumor efficacy, B-381 can benefit from a secondary drug delivery system to bring the drug to the vicinity of the tumor and reduce pharmacokinetic elimination. Such studies are ongoing for developing a drug delivery system to improve the tumor delivery of B-381. 
CONCLUSIONS
In conclusion, we have reported the synthesis and preliminary biological evaluation of B-381 as a novel agent for BNCT. B-381 had minimal cytotoxicity, preferentially accumulated in hypoxic cells, and demonstrated longer tumor retention in an in vivo glioma model compared to BPA. It achieved significant tumor/normal tissue ratios as well as tumor/blood ratios which are in compliance with the requirements for selective and successful BNCT. However, it presented relatively poor pharmacokinetics. B-381 presents a new class of BNCT agents in which their selectivity to tumors is based on tumor metabolism and biology. Future studies are warranted to synthesize similar compounds with better pharmacokinetics, or for the development of drug delivery systems to improve boron delivery to the tumor environment.
